NFKB1 and rheumatoid arthritis: Collectively, these findings underscore that siRNA therapeutics exert multi-layered immunomodulatory effects—not only by directly silencing pro-inflammatory signaling molecules such as NF-κB, JAK2, and STAT3, but also by reprogramming the immune landscape of the RA microenvironment through macrophage repolarization and transcriptional re-balancing of downstream targets.